Literature DB >> 24132671

Epiretinal membrane: a treatable cause of visual disability in myotonic dystrophy type 1.

Hannah M Kersten1, Richard H Roxburgh, Nicholas Child, Philip J Polkinghorne, Chris Frampton, Helen V Danesh-Meyer.   

Abstract

A wide range of ocular abnormalities have been documented to occur in patients with myotonic dystrophy type 1. The objectives of this study were to investigate the macular and optic nerve morphology using optical coherence tomography in patients with myotonic dystrophy type 1. A total of 30 myotonic dystrophy type 1 patients and 28 controls were recruited for participation. All participants underwent a thorough ophthalmologic examination, including spectral-domain optical coherence tomography of the macula and retinal nerve fibre layer. Images were reviewed by a retinal specialist ophthalmologist, masked to the diagnosis of the participants. Average macular thickness was significantly greater in the myotonic dystrophy group compared to controls [327.3 μm vs. 308.5 μm (p < 0.001)]. Macular thickness was significantly greater (p < 0.005) in five of the nine macular regions. The increase in macular thickness was due to the increased prevalence of epiretinal membranes in the myotonic dystrophy patient group (p = 0.0002): 48.2 % of myotonic dystrophy patient eyes had evidence of epiretinal membrane, compared with 12.5 % of control eyes. Examination revealed that 56.7 % of myotonic dystrophy patients had an epiretinal membrane in at least one eye. Visual acuity was reduced due to the presence of epiretinal membrane in six patient eyes and none of the control eyes. The presence of an epiretinal membrane was significantly correlated with increasing age in the patient group. We report an increased prevalence of epiretinal membrane in the myotonic dystrophy type 1 group. This may be a previously under-recognised form of visual impairment in this group. Epiretinal membranes can be treated surgically. We suggest that, in addition to a comprehensive clinical examination, optical coherence tomography examination is implemented as part of an ophthalmological assessment for the myotonic dystrophy type 1 patient with reduced visual acuity.

Entities:  

Mesh:

Year:  2013        PMID: 24132671     DOI: 10.1007/s00415-013-7141-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  Prevalence and risk factors of epiretinal membrane in Asian Indians.

Authors:  Victor Koh; Carol Y Cheung; Wan-Ling Wong; Chui-Min Cheung; Jie Jin Wang; Paul Mitchell; Christine Younan; Seang Mei Saw; Tien Y Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

2.  Rab3A mediates vesicle delivery at photoreceptor ribbon synapses.

Authors:  Miao Tian; C Shan Xu; Rachel Montpetit; Richard H Kramer
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

3.  Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy.

Authors:  Marie Kierkegaard; Anna Tollbäck
Journal:  Neuromuscul Disord       Date:  2007-09-14       Impact factor: 4.296

Review 4.  Age-related cellular proliferation at the vitreoretinal juncture.

Authors:  D McLeod; P S Hiscott; I Grierson
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

5.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

6.  Eye movements in myotonic dystrophy.

Authors:  E Bollen; J C den Heyer; M H Tolsma; S Bellari; J E Bos; A R Wintzen
Journal:  Brain       Date:  1992-04       Impact factor: 13.501

7.  Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats.

Authors:  L Chang; T Ernst; D Osborn; W Seltzer; M Leonido-Yee; R E Poland
Journal:  Arch Neurol       Date:  1998-03

8.  Ultrastructure of cataract in myotonic dystrophy.

Authors:  J Eshaghian; W F March; W Goossens; N S Rafferty
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-03       Impact factor: 4.799

Review 9.  Myotonic dystrophy: RNA pathogenesis comes into focus.

Authors:  Laura P W Ranum; John W Day
Journal:  Am J Hum Genet       Date:  2004-04-02       Impact factor: 11.025

10.  Hypotony and aqueous humor dynamics in myotonic dystrophy.

Authors:  S D Walker; R F Brubaker; S Nagataki
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-06       Impact factor: 4.799

View more
  5 in total

Review 1.  Ophthalmic manifestations of inherited neurodegenerative disorders.

Authors:  Hannah M Kersten; Richard H Roxburgh; Helen V Danesh-Meyer
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

2.  Ophthalmic findings in myotonic dystrophy type 2: a case series.

Authors:  Hannah M Kersten; Helen V Danesh-Meyer; Richard H Roxburgh
Journal:  J Neurol       Date:  2016-11-02       Impact factor: 4.849

3.  Ocular Findings of Myotonic Dystrophy Type 1 in the Korean Population.

Authors:  Se Hyun Choi; Hee Kyung Yang; Jeong-Min Hwang; Kyung Seok Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-27       Impact factor: 3.117

4.  The New Zealand Neuromuscular Disease Patient Registry; Five Years and a Thousand Patients.

Authors:  Miriam J Rodrigues; Gina L O'Grady; Graeme Hammond-Tooke; Alexa Kidd; Donald O Love; Ronelle K Baker; Richard H Roxburgh
Journal:  J Neuromuscul Dis       Date:  2017

Review 5.  Retinal Imaging of Infants on Spectral Domain Optical Coherence Tomography.

Authors:  Anand Vinekar; Shwetha Mangalesh; Chaitra Jayadev; Ramiro S Maldonado; Noel Bauer; Cynthia A Toth
Journal:  Biomed Res Int       Date:  2015-07-06       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.